The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)
| Autor: | Michael L. Cibull, Edward J. Pavlik, James L Wilder, Warner K. Huh, J. Hunter, Paul D. DePriest, M. B. Reedy, L. Puls, Robert V. Higgins, J.R. van Nagell, Paola A. Gehrig, Richard J. Kryscio, Frederick R. Ueland, W. Merritt, Susan C. Modesitt, Brian M. Slomovitz, Kelly J. Manahan, David E. Cohn, J. Giesler, Charles S. Dietrich, M. Powell |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Cyclophosphamide Paclitaxel medicine.medical_treatment Carboplatin chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols Carcinoma medicine Humans Cystadenocarcinoma Survival rate Aged Neoplasm Staging Retrospective Studies Cisplatin Aged 80 and over Chemotherapy business.industry Obstetrics and Gynecology Middle Aged medicine.disease Carcinoma Papillary Surgery Cystadenocarcinoma Serous Survival Rate Oncology chemistry Chemotherapy Adjuvant Uterine Neoplasms Female Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Gynecologic oncology. 99(3) |
| ISSN: | 0090-8258 |
| Popis: | Objective. To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. A retrospective multi-institutional investigation was performed to identify surgically staged patients with Stage I UPSC who were (1) treated after surgery with 3–6 courses of platinum-based chemotherapy without radiation from 1990–2003, and (2) followed for a minimum of 12 months, or until recurrence. Results. Six patients (IA—2, IB—3, IC—1) were treated with carboplatin (AUC 6) or cisplatin (50 mg/m 2 ) alone. One patient recurred to the vagina, was treated with chemo-radiation, and is alive and well at 122 months. One patient recurred to the lung, liver, and brain, and died of disease at 24 months. The remaining 4 patients are alive with no evidence of disease 15–124 months (mean 62 months) after treatment. Two patients (IB-1, IC-1) were treated with cisplatin (50 mg/m 2 ) and cyclophosphamide (1000 mg/m 2 ), and both are alive and well with no evidence of disease 75 and 168 months after treatment. Twenty-one patients (IA—5, IB—13, IC—3) were treated with a combination of carboplatin (AUC 6) and paclitaxel (135 mg/m 2 –175 mg/m 2 ). One patient recurred to the vagina after 3 cycles of carboplatin/paclitaxel, and was treated with chemo-radiation. She is now without evidence of disease 10 months after treatment. At present, all 21 patients with Stage I UPSC treated following surgical staging with carboplatin/paclitaxel chemotherapy are alive and well with no evidence of disease 10–138 months (mean 41 months) after treatment. Conclusion. Combination carboplatin/paclitaxel chemotherapy following surgery is effective in the treatment of Stage I UPSC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect